Skip to main content
PMC home page
Cytotechnology logoLink to Cytotechnology
. 1998 Sep;27(1-3):149–164. doi: 10.1023/A:1008008719699

Topoisomerase I inhibitors and drug resistance

Ralph E Parchment 1, Augusto Pessina 2
PMCID: PMC3449562  PMID: 19002789

Abstract

DNA topoisomerase I is a nuclear enzyme which catalyzes the conversion of the DNA topology by introducing single-strand breaks into the DNA molecule. This enzyme represents a novel and distinct molecule target for cancer therapy by antitopoisomerase drugs belonging to the campthotecin series of antineoplastics. As many tumors can acquire resistance to drug treatment and become refractary to the chemotherapy it is very important to investigate the mechanisms involved in such a drug resistance for circumventing the phenomenon. This article describes the role of topoisomerase I in cell functions and the methods used to assess its in vitro catalytic activity. It reviews the mechanisms of cytotoxicity of the most specific antitopoisomerase I drugs by considering also the phenomenon of drug resistance. Some factors useful to drive the future perspectives in the development of new topoisomerase I inhibitors are also evidenced and discussed.

Keywords: camptothecin, drug resistance, topo I inhibitors, topoisomerase I

Full Text

The Full Text of this article is available as a PDF (124.1 KB).

References

  1. Abigerges D, Armand JP, Chabot GG, Bruno R, Bissery MC, Bayssas M, Klink-Alakl M, Clavel M, Catimel G. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients. Anticancer Drugs. 1996;7:166–74. doi: 10.1097/00001813-199602000-00004. [DOI] [PubMed] [Google Scholar]
  2. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kuzunoki Y, Takemoto Y, Okada K. Characterization of a mammalian mutant with camptothecin resistant DNA topoisomerase I. Proc Natl Acad Sci USA. 1987;84:5565–69. doi: 10.1073/pnas.84.16.5565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Andrews BJ. Gene expression-dialogue with the cell cycle. Nature. 1992;355:393–4. doi: 10.1038/355393a0. [DOI] [PubMed] [Google Scholar]
  4. Baguley BC, Holdway KM, Fray LM. Design of DNAintercalators to overcome topoisomerase II-mediated multidrug resistance. J Natl Cancer Inst. 1990;82:398–402. doi: 10.1093/jnci/82.5.398. [DOI] [PubMed] [Google Scholar]
  5. Baker SD, Wadkins RM, Stewart CF, Beck WT, Danks MK. Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy. Cytometry. 1995;19:134–45. doi: 10.1002/cyto.990190208. [DOI] [PubMed] [Google Scholar]
  6. Barrett JF, Sutcliffe YA, Gootz TD. In vitroassay used to measure the activity of topoisomerases. Antimicrob. Agents Chemother. 1990;34:1–7. doi: 10.1128/aac.34.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Barronco SC. Cellular and molecular effects of Adriamycin on dividing and non dividing cells. Pharmac Ther. 1984;24:303–319. doi: 10.1016/0163-7258(84)90007-x. [DOI] [PubMed] [Google Scholar]
  8. Beck WT. The cell biology of multiple drug resistance. Biochem Pharmacol. 1987;36:2879–88. doi: 10.1016/0006-2952(87)90198-5. [DOI] [PubMed] [Google Scholar]
  9. Beck WT, Danks MK. Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin Cancer Biol. 1991;2:235–44. [PubMed] [Google Scholar]
  10. Beck WY, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM. Pharmacological molecular and cytogenetic analysis of ‘atypical’ multidrug-resistant human leukemic lines. Cancer Res. 1987;47:5455–60. [PubMed] [Google Scholar]
  11. Beidler DR, Cheng YC. Camptothecin induction of a time-and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol. 1995;47:907–14. [PubMed] [Google Scholar]
  12. Besterman JM. Topoisomerase I inhibition by the camptothecin analog Gl147211C. From the laboratory to the clinic. Ann N Y Acad Sci. 1996;803:202–9. doi: 10.1111/j.1749-6632.1996.tb26389.x. [DOI] [PubMed] [Google Scholar]
  13. Boege F, Straub T, Kehr A, Boesenberg C, Christiansen K, Andersen A, Jakob F, Kohrle J. Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I. J Biol Chem. 1996;271:2262–70. doi: 10.1074/jbc.271.4.2262. [DOI] [PubMed] [Google Scholar]
  14. Bronstein IB, Vorobyev S, Timofeev A, Jolles CJ, Alder SL, Holden JA. Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. Onc Res. 1996;8:17–25. [PubMed] [Google Scholar]
  15. Buckwalter CA, Lin AH, Tanizawa A, et al. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res. 1996;6:1674–81. [PubMed] [Google Scholar]
  16. Burke TG, Mi Z. Preferential binding of carboxylate form of camptothecin by human serum albumin. Analytical Biochem. 1993;21:285–87. doi: 10.1006/abio.1993.1325. [DOI] [PubMed] [Google Scholar]
  17. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability. J Med Chem. 1994;37:401–6. doi: 10.1021/jm00027a005. [DOI] [PubMed] [Google Scholar]
  18. Carrigan SW, Fox PC, Wall ME, Wani MC, Bowen JP. Comparative molecular field analysis and molecular modeling studies of 20-(S)-camptothecin analogs as inhibitors of DNA topoisomerase I and anticancer/antitumor agents. J Comput Aided Mol Des. 1997;11:71–8. doi: 10.1023/a:1008027528218. [DOI] [PubMed] [Google Scholar]
  19. Champoux JJ. DNA is linked to the rat liver nicking-closing enzyme by a phosphodiester bond to tyrosine. J Biol Chem. 1981;256:4805–09. [PubMed] [Google Scholar]
  20. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res. 1991;51:6039–44. [PubMed] [Google Scholar]
  21. Chen AY, Yu C, Bodley A, Peng LF, Liu LF. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res. 1993;53:1332–37. [PubMed] [Google Scholar]
  22. Chin KV, Pastan I, Gottesman MM. Function and regulation of the human multidrug resistance gene. Adv. Cancer Res. 1993;60:157–80. doi: 10.1016/s0065-230x(08)60825-8. [DOI] [PubMed] [Google Scholar]
  23. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science. 1992;255:459–62. doi: 10.1126/science.1346476. [DOI] [PubMed] [Google Scholar]
  24. Clynes M. Cellular models for multiple drug resistance in cancer. In Vitro Cell. Dev Biol. 1993;29A:171–79. doi: 10.1007/BF02634176. [DOI] [PubMed] [Google Scholar]
  25. Clynes M, Redmond A, Heenan M. Recent developments in research on multiple drug-resistance in cancer cells. Cancer J. 1990;3:34–39. [Google Scholar]
  26. Cobb J, Reddy RK, Park C, Handel MA. Analysis of expression and function of topoisomerase I and II during meiosis in male mice. Mol Reprod Develop. 1997;46:489–98. doi: 10.1002/(SICI)1098-2795(199704)46:4<489::AID-MRD7>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  27. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: Topotecan and Irinotecan. Cancer Treatment Rev. 1994;20:73–96. doi: 10.1016/0305-7372(94)90011-6. [DOI] [PubMed] [Google Scholar]
  28. Cummings J, Macpherson JS, Meikle I, Smyth JF. Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance. Biochem Pharmacol. 1996;52:979–90. doi: 10.1016/0006-2952(96)00301-2. [DOI] [PubMed] [Google Scholar]
  29. Dahut W, Brillhart N, Takimoto C, Allegra C, Hamilton JM, Sorensen JM, Arbuck S, Chen A and Grem J (1994) A phase I trial of 9-aminocamptothecin (9-AC) in adult patients with solid tumors. Proc Am Soc Clin Oncol 13: A345.
  30. Danks MK, Garret KE, Marion RC, et al. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res. 1996;56:1664–73. [PubMed] [Google Scholar]
  31. D'arpa P and Liu FL (1989) Topoisomerase-targeting antitumor-drugs. Biochim Biophis Acta 989: 163-77. [DOI] [PubMed]
  32. Deady LW, Kaye AJ, Finlay GJ, Baguley BC, Denny WA. Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors. J Med Chem. 1997;40:2040–6. doi: 10.1021/jm970044r. [DOI] [PubMed] [Google Scholar]
  33. Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC, Henner WD, Geldenberg GJ. Multifactori-alresistance to Adriamycin: relationship of DNA repair, glutathione transferase activity drug efflux, and P-glycoprotein in cloned cell lines of Adriamycin-sensitive and resistant P388 leukemia. Cancer Res. 1988;48:3595–602. [PubMed] [Google Scholar]
  34. Endicott JA, Ling V. The biochemistry of P-glycoproteinmediated multridrug resistance. Annu Rev Biochem. 1989;58:351–375. doi: 10.1146/annurev.bi.58.070189.001033. [DOI] [PubMed] [Google Scholar]
  35. Eng WK, Faucette L, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol. 1988;34:755–60. [PubMed] [Google Scholar]
  36. Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP, Johnson RK. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol. 1990;38:471–80. [PubMed] [Google Scholar]
  37. EORTC (1992) Reports on Topoisomerase I Inhibitors from the 7th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, March 17-20.
  38. Erickson-Miller CL, May RD, Tomaszewski JE, Osborn B, Murphy MJ, Page JG, Parchment RE. Differential toxicity of camptothecin, topotecan, and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Can Chem Pharmacol. 1997;39:467–72. doi: 10.1007/s002800050600. [DOI] [PubMed] [Google Scholar]
  39. Ferguson PJ, Fisher MH, Stephenson J, Li D-H, Zhou B-S, Cheng Y-C. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res. 1988;48:5956. [PubMed] [Google Scholar]
  40. Fojo AT, Ueda K, Slamon DJ, Poplank DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA. 1987;84:265–269. doi: 10.1073/pnas.84.1.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD. Activity of 9-dimethlyaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol. 1994;34:171–74. doi: 10.1007/BF00685936. [DOI] [PubMed] [Google Scholar]
  42. Fujimori A, Gupta M, Hoki Y, Pommier Y. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair. Mol Pharmacol. 1996;50:1472–8. [PubMed] [Google Scholar]
  43. Fukuda M, Nishio K, Kanzawa F, Ogasawara H, Ishida T, Arioka H, Bojanowski K, Oka M, Saijo N. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res. 1996;56:789–93. [PubMed] [Google Scholar]
  44. Funabashi Y, Horiguchi T, Iinuma S, Tanida S, Harada S. TAN-1496 A, C and E, diketopiperazine antibiotics with inhibitory activity against mammalian DNA topoisomerase I. J Antibiot. 1994;47:1202–18. doi: 10.7164/antibiotics.47.1202. [DOI] [PubMed] [Google Scholar]
  45. Funayama Y, Nishio K, Wakabayashi K, Nagao M, Shimoi K, Ohira T, Hasegawa S, Saijo N. Effects of beta-and gammacarboline derivatives of DNA topoisomerase activities. Mutat Res. 1996;349:183–91. doi: 10.1016/0027-5107(95)00176-x. [DOI] [PubMed] [Google Scholar]
  46. Gellert M. DNA topoisomerases. Annu Rev Biochem. 1981;50:879–910. doi: 10.1146/annurev.bi.50.070181.004311. [DOI] [PubMed] [Google Scholar]
  47. Germann UA. P-glycoprotein-A mediator of multidrug resistance in tumor cells. Eur J Cancer. 1996;6:927–44. doi: 10.1016/0959-8049(96)00057-3. [DOI] [PubMed] [Google Scholar]
  48. Gerrits CJ, Creemers GJ, Schellens JH, Wissel P, Planting AS, Kunka R, Selinger K, de Boer-Dennert M, Marijnen Y, Harteveld M, Verweij J. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration. Br J Cancer. 1996;73:744–50. doi: 10.1038/bjc.1996.130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science. 1989;246:1046–48. doi: 10.1126/science.2555920. [DOI] [PubMed] [Google Scholar]
  50. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R, Potmesil M. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res. 1991;51:3052–55. [PubMed] [Google Scholar]
  51. Gobert C, Bracco L, Rossi F, Olivier M, Tazi J, Lavelle, Larsen AK, Riou JF. Modulation of DNA topoisomerase I activity by p53. Biochem. 1996;35:5778–86. doi: 10.1021/bi952327w. [DOI] [PubMed] [Google Scholar]
  52. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880) Cancer Chemother Reports. 1970;54:461–70. [PubMed] [Google Scholar]
  53. Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, Smith BR, Hurowitz L, DeLisa A, Donehower RC, Noe DA. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Disp. 1992;20:706–13. [PubMed] [Google Scholar]
  54. Gromova II, Kjeldsen E, Svejstrup JQ, Alsner J, Christiansen K, Westergaard O. Characterization of an altered DNA catalysis of a camptothecin resistant eukaryotic topoisomerase I. Nucleic Acid Res. 1993;21:593–600. doi: 10.1093/nar/21.3.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994;54:3723–5. [PubMed] [Google Scholar]
  56. Gupta M, Abdel-Megeed M, Hoki Y, Kohlhagen G, Paull K, Pommier Y. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517. Mol Pharmacol. 1995;48:658–65. [PubMed] [Google Scholar]
  57. Gupta RS, Gupta R, Eng B, Lock RB, Ross WE, Hertzberg RP, Caranfa MJ, Johnson RK. Camptothecin resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res. 1988;48:6404–10. [PubMed] [Google Scholar]
  58. Hait WN, Aftab DT. Rational design and preclinical pharmacology of drugs for reversing multidrug resistance. Biochem Pharmacol. 1992;43:103–7. doi: 10.1016/0006-2952(92)90667-8. [DOI] [PubMed] [Google Scholar]
  59. Heck MMS, Hittelman WN, Earnshaw WC. Differentialexpression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA. 1988;85:1086–90. doi: 10.1073/pnas.85.4.1086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH. Effect of p-glycoprotein expression of the accumulation and cytotoxicity of topotecan (SK&f 104864) a new camptothecin analogue. Cancer Res. 1992;52:2268–70. [PubMed] [Google Scholar]
  61. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, Blum RH. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol. 1994;12:553–59. doi: 10.1200/JCO.1994.12.3.553. [DOI] [PubMed] [Google Scholar]
  62. Hoki Y, Fujimori A, Pommier Y. Differential cytotoxicity of clinically important camptothecin derivatives in Pglycoprotein-overexpressing cell lines. Cancer Chemother Pharmacol. 1997;40:433–8. doi: 10.1007/s002800050682. [DOI] [PubMed] [Google Scholar]
  63. Horwitz SB. Antibiotics. In: Corcoran W., Hahn FE, editors. Mechanism of action of antimicrobial and antitumor agents. N.Y.: Springer Verlag; 1975. pp. 48–57. [Google Scholar]
  64. Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res. 1973;33:2834–36. [PubMed] [Google Scholar]
  65. Houghton PJ, Cheshire PJ, Myers I, Stewart CF, Synold TW, Oughton JA. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and chidhood solid tumors. Cancer Chemother Pharmacol. 1992;31:229–59. doi: 10.1007/BF00685553. [DOI] [PubMed] [Google Scholar]
  66. Hsiang H, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, Kirschenbaum S, Silber R, Potmesil M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res. 1989;49:4385–89. [PubMed] [Google Scholar]
  67. Hsiang T-S. DNA Topoisomerases. Curr Opin Cell Biol. 1992;4:396–400. doi: 10.1016/0955-0674(92)90004-v. [DOI] [PubMed] [Google Scholar]
  68. Hsiang YH, Herzberg R, Hecht S, Liu LF. Camptothecin induces protein linked DNA breaks via mammalian DNA topoisomerases. J Biol Chem. 1985;260:14873–78. [PubMed] [Google Scholar]
  69. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989;49:5077–82. [PubMed] [Google Scholar]
  70. Hsiang YH, Wu HY, Liu FL. Proliferation dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res. 1988;48:3230–35. [PubMed] [Google Scholar]
  71. Husain I, Mohler JL, Seigler HF, Besterman JM. Elevation topoisomerase I messenger RNA, protein and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 1994;54:539–46. [PubMed] [Google Scholar]
  72. Hussy P, Maass G, Tümmler B, Grosse F, Schomburg U. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase α primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother. 1986;29:1073–78. doi: 10.1128/aac.29.6.1073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Ikuno N, Soda H, Watanabe M, Oka M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst. 1995;87:1876–83. doi: 10.1093/jnci/87.24.1876. [DOI] [PubMed] [Google Scholar]
  74. Ishii K, Futaki S, Uchiyama H, Nagasawa K, Andoh T. Mechanism of inhibition of mammalian DNA topoisomerase I by heparin. Biochem J. 1987;241:111–16. doi: 10.1042/bj2410111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Ishimi Y, Nishizawa M, Andoh T. Characterization of a camptothecin-resistant human DNA topoisomerase I in an in vitrosystem for Simian virus 40 DNA replication. Eur J Biochem. 1991;202:835–39. doi: 10.1111/j.1432-1033.1991.tb16440.x. [DOI] [PubMed] [Google Scholar]
  76. Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, van der Valk P, Scheper RJ. Major vault protein LRP-related multidrug resistance. Eur J Cancer. 1996;6:976–84. doi: 10.1016/0959-8049(96)00053-6. [DOI] [PubMed] [Google Scholar]
  77. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 1989;49:1465–69. [PubMed] [Google Scholar]
  78. Jaxel C, Capranico G, Wasserman K, Kerrigan D, Kohn KW, Pommier Y. DNA sequence at sites of topoisomerase I cleavage induced by Camptothecin in SV40 DNA. In: Potmesil M, Kohn KW, editors. DNA topoisomerases in cancer. New York: Oxford University Press; 1991. pp. 182–195. [Google Scholar]
  79. Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M. In vitrocross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br J Cancer. 1997;75:869–77. doi: 10.1038/bjc.1997.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Juan CC, Hwang J, Liu AA, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Zhang H, Wang JC, Liu LF. Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. Proc Natl Acad Sci USA. 1988;85:8910–17. doi: 10.1073/pnas.85.23.8910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Kafiani CA, Bronstein IB, Timofeen AV, Gromova II, Terskikh VV. DNA topoisomerases and regulation of cell proliferation. Adv Enzyme Regul. 1986;25:439–57. doi: 10.1016/0065-2571(86)90028-2. [DOI] [PubMed] [Google Scholar]
  82. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood. 1993;81:1146–51. [PubMed] [Google Scholar]
  83. Kanter PM, Schwartz HS. A fluorescence enhancement assay for cellular DNA damage. Mol Pharmacol. 1982;22:145–51. [PubMed] [Google Scholar]
  84. Kanzawa F, Sugimoto Y, Minato K, et al. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small-cell lung cancer: Characterization and mechanism of resistance. Cancer Res. 1990;50:5919–24. [PubMed] [Google Scholar]
  85. Khon KW, Ewig RAG, Erickson LC, Zwelling LA. Measurement of strand breaks and cross links by alkaline elution. In: Friedberg EC, Hanawalt PC, editors. DNA repair: a laboratory manual of research procedures. New York: Marcel Dekker, Inc.; 1981. pp. 379–401. [Google Scholar]
  86. Kim JS, Gatto B, Yu C, Liu A, Liu LF, LaVoie EJ. Substituted 2, 5′-Bi-1H-benzimidazoles: topoisomerase I inhibition and cytotoxicity. J Med Chem. 1996;39:992–8. doi: 10.1021/jm950412w. [DOI] [PubMed] [Google Scholar]
  87. Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK, Hertzberg RP. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem. 1991;34:98–107. doi: 10.1021/jm00105a017. [DOI] [PubMed] [Google Scholar]
  88. Kjeldsen E, Bonven BJ, Andoh T, Ishii K, Okada K, Bolund L, Westergaard O. Characterization of a camptothec in resistant human DNA topoisomerase I. J Biol Chem. 1988;263:3912–16. [PubMed] [Google Scholar]
  89. Knab AM, Fertala J, Bjornsti MA. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants. J Biol Chem. 1993;268:22322–30. [PubMed] [Google Scholar]
  90. Kubota N, Kanzawa F, Nishio K, Takeda Y, Ohmori T, Fujiwara Y, Terashima Y, Saijo N. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem Biophys Res Commun. 1992;188:571–7. doi: 10.1016/0006-291x(92)91094-7. [DOI] [PubMed] [Google Scholar]
  91. Lefevre D, Riou J-F, Ahomadegbe JC, et al. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and the acidic glutathione S transferase. Biochem Pharmacol. 1991;41:1967–79. doi: 10.1016/0006-2952(91)90138-u. [DOI] [PubMed] [Google Scholar]
  92. Li HL, Fraser TJ, Olin EJ, Bhuyan BK. Action of camptothecin on mammalian cells in culture. Cancer Res. 1972;32:2643–50. [PubMed] [Google Scholar]
  93. Lin JH, Castora FJ. Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA. Arch Biochem Biophys. 1995;324:293–9. doi: 10.1006/abbi.1995.0042. [DOI] [PubMed] [Google Scholar]
  94. Liu LF. DNA topoisomerase-enzymes that catalyse the-breacking and rejoining of DNA. Crit Rev Biochem. 1983;15:1–24. doi: 10.3109/10409238309102799. [DOI] [PubMed] [Google Scholar]
  95. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989;58:351–75. doi: 10.1146/annurev.bi.58.070189.002031. [DOI] [PubMed] [Google Scholar]
  96. Liu LF (1990) DNA topoisomerases in drug resistance and cancer chemotherapy. The third Conference on DNA Topoisomerase in therapy. Oct 15-18, New York, p. 25.
  97. Liu LF, Rowe TC, Yang L, Tewey KM, Chen GL. Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem. 1983;258:15365–70. [PubMed] [Google Scholar]
  98. Loe DW, Deeley RG, Cole SPC. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer. 1996;6:945–57. doi: 10.1016/0959-8049(96)00046-9. [DOI] [PubMed] [Google Scholar]
  99. Ludescher C, Gattringer C, Drach J, Hofmann J, Grunicke H. Rapid functional assay for the detection of multidrug-resistant cells using the fluorescent dye rhodamine-123. Blood. 1991;78:1385–87. [PubMed] [Google Scholar]
  100. Madden KR, Stewart L, Champoux JJ. Preferential binding of human topoisomerase I to superhelical DNA. EMBO J. 1995;14:5399–409. doi: 10.1002/j.1460-2075.1995.tb00224.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Makhey D, Gatto B, Yu C, Liu A, Liu LF, LaVoie EJ. Coralyne and related compounds as mammalian topoisomerase I and topoisomerase II poisons. Bioorg Med Chem. 1996;4:781–91. doi: 10.1016/0968-0896(96)00054-5. [DOI] [PubMed] [Google Scholar]
  102. Marshall ES, Finlay GJ, Matthews JHL, Shaw JHF, Nixon J, Baguley BC. Microculture-based chemosensitivity testing: a feasibility study camparting freshly explanted human melanoma cells with human melanoma cell lines. J Natl Cancer Inst. 1992;84:341–44. doi: 10.1093/jnci/84.5.340. [DOI] [PubMed] [Google Scholar]
  103. Masin JS, Berger SJ, Setrakian S, Stepnik DW, Berger NA. Topoisomerase I activity in squamous cell carcinoma of the head and neck. Laring. 1995;105:1191–6. doi: 10.1288/00005537-199511000-00010. [DOI] [PubMed] [Google Scholar]
  104. McLeod HL, Douglas F, Oates M, Symonds RP, Prakash D, van der Zee AGJ, Kaye SB, Brown R, Keith WN. Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer. 1994;59:607–611. doi: 10.1002/ijc.2910590506. [DOI] [PubMed] [Google Scholar]
  105. Meikle I, Cummings J, Macpherson JS, Smyth JF. Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs. Anticancer Drug Des. 1995;10:515–27. [PubMed] [Google Scholar]
  106. Mi Z, Burke TG. Differential interaction of camptothecin lactone and carboxylate forms with human blood components. Biochemistry. 1994;33:10325–36. doi: 10.1021/bi00200a013. [DOI] [PubMed] [Google Scholar]
  107. Mi Z, Burke TG. Marked interspecies variations concerning the interaction of camptothecin with serum albumin: a frequency-domain fluorescence spectroscopic study. Biochemistry. 1994;33:12540–45. doi: 10.1021/bi00208a002. [DOI] [PubMed] [Google Scholar]
  108. Muggia FM, Creaven PJ, Hansen H, Cohen MH, Selawry OS. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Reports. 1972;56:515–21. [PubMed] [Google Scholar]
  109. Muller MT, Pfund WP, Mehta VB, et al. Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. EMBO J. 1985;4:1237–43. doi: 10.1002/j.1460-2075.1985.tb03766.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Murren JR, Beidler DR, Cheng YC. Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks. Ann N Y Acad Sci. 1996;803:74–92. doi: 10.1111/j.1749-6632.1996.tb26378.x. [DOI] [PubMed] [Google Scholar]
  111. Nakatsu S, Kondo S, Kondo Y, Yin D, Peterson JW, Kaakaji R, Morimura T, Kikuchi H, Takeuchi J, Barnett GH. Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol. 1997;39:417–23. doi: 10.1007/s002800050592. [DOI] [PubMed] [Google Scholar]
  112. Niimi S, Nakagawa K, Sugimoto Y, Nishio K, Fujiwara Y, Yokoyama S, Terashima Y, Saijo N. Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res. 1992;52:328–33. [PubMed] [Google Scholar]
  113. Nitiss JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer. 1996;6:958–66. doi: 10.1016/0959-8049(96)00056-1. [DOI] [PubMed] [Google Scholar]
  114. Nooter K, Herweijer H. Multidrug resistance (mdr)genes in human cancer. Br J Cancer. 1991;63:663–9. doi: 10.1038/bjc.1991.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Oguro M, Seki Y, Okada K, Andoh T. Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. Biomed Pharmacother. 1990;44:209–216. doi: 10.1016/0753-3322(90)90026-6. [DOI] [PubMed] [Google Scholar]
  116. Pantazis P, Early JA, Mendoza JT, DeJesus AR, Giovanella BC. Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res. 1994;54:771–6. [PubMed] [Google Scholar]
  117. Pantazis P, Harris N, Mendoza J, Giovanella B. Conversion of 9-nitro-camptothecin to 9-amino-camptothecin by human blood cells in vitro(letter) Eur J Haematol. 1994;53:246–8. doi: 10.1111/j.1600-0609.1994.tb00199.x. [DOI] [PubMed] [Google Scholar]
  118. Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJ, Jr, Stehlin JS, Jr, Giovanella BC. Complete inhibition of growth followed by death of human malignant melanoma cells in vitroand regression of human melanoma Xenografts in immunodeficient mice induced by camptothecin. Cancer Res. 1992;52:3980–87. [PubMed] [Google Scholar]
  119. Pantazis P, Mendoza J, DeJesus A, Early J, Shaw M, Giovanella BC. Development of resistance to 9-nitro-camptothecin by human leukemia U-937 cells in vitrocorrelates with altered sensitivities to several anticancer drugs. Anticancer Drugs. 1994;5:473–9. doi: 10.1097/00001813-199408000-00014. [DOI] [PubMed] [Google Scholar]
  120. Perez-Stable C, Shen CC, Shen CKJ. Enrichment and depletion of Hela topoisomerase I recognition sites among specific types of DNA elements. Nucl Acids Res. 1988;16:7975–93. doi: 10.1093/nar/16.16.7975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Pessina A. Topoisomerase I in multiple drug resistance. Cytotechnology. 1993;12:127–135. doi: 10.1007/BF00744661. [DOI] [PubMed] [Google Scholar]
  122. Pommier Y, Kerrigan D, Hartman KD, et al. Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C. J Biol Chem. 1990;265:9418–22. [PubMed] [Google Scholar]
  123. Pommier Y, Zwelling LA, Kao-Shan CS, Whang-Peng J, Bradley MO. Correlation between intercalator induced DNA strand breaks and sister chromatid exchanges mutations and cytotoxicity in Chinese hamster cells. Cancer Res. 1985;45:3143–48. [PubMed] [Google Scholar]
  124. Pommier Y, Gupta M, Valenti, Nieves-Neira W. Cellular resistance to camptothecins. In: Pantazis P, Giovanella BC, Rothenberg ML, editors. The Camptothecin: From Discovery to the Patient. New York: Annals NY Acad Sci; 1996. pp. 2268–78. [DOI] [PubMed] [Google Scholar]
  125. Potmesil M, Hsiang Y-H, Liu LF, Bank B, Grossberg H, Kirschenbaum S, Forlenza TJ, Penziner A, Kanganis D, Knowles D, Traganos F, Silber R. Resistance of human leukemic and normal lynphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res. 1988;48:3537–43. [PubMed] [Google Scholar]
  126. Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, Avery L, Meyer WH. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol. 1994;12:539–43. doi: 10.1200/JCO.1994.12.3.539. [DOI] [PubMed] [Google Scholar]
  127. Priel E, Showalter SD, Blair DG. Inhibition of humanimmunodeficiency virus (HIV-1) replication in vitroby non cytotoxic doses of camptothecin, a topoisomerase I inhibitor. AIDS Res Hum Retrovirus. 1991;7:65–72. doi: 10.1089/aid.1991.7.65. [DOI] [PubMed] [Google Scholar]
  128. Prost S. Mechanisms of resistance to topoisomerases poisons. Gen Pharmacol. 1995;26:1673–84. doi: 10.1016/0306-3623(95)00108-5. [DOI] [PubMed] [Google Scholar]
  129. Qian X, Beck WT. Binding of an optically pure photoaffinity analogue of verapamil LU-49888 to P-glycoprotein from multidrug resistant human leukemic cell lines. Cancer Res. 1990;50:1132–1137. [PubMed] [Google Scholar]
  130. Ray S, Majumder HK, Chakravarty AK, Mukhopadhyay S, Gil RR, Cordell GA. Amarogentin, a naturally occurring secoiridoid glycoside and a newly recognized inhibitor of topoisomerase I from Leishmania donovani. J Nat Prod. 1996;59:27–9. doi: 10.1021/np960018g. [DOI] [PubMed] [Google Scholar]
  131. Ray S, Sadhukhan PK, Mandal NB, Mahato SB, Majumder HK. Dual inhibition of DNA topoisomerases of Leishmania donovani by novel indolyl quinolines. Biochem Biophys Res Commun. 1997;230:171–5. doi: 10.1006/bbrc.1996.5874. [DOI] [PubMed] [Google Scholar]
  132. Riou JF, Grondard L, Naudin A, Bailly C. Effects of two distamycin-ellipticine hybrid molecules on topoisomerase I and II mediated DNA cleavage: relation to cytotoxicity. Biochem Pharmacol. 1995;50:424–8. doi: 10.1016/0006-2952(95)00132-j. [DOI] [PubMed] [Google Scholar]
  133. Rodriguez-Campos A, Azorin F, Portugal J. Influence of elsamicin A on the activity of mammalian topoisomerase I. Biochemistry. 1996;35:11177–82. doi: 10.1021/bi960583i. [DOI] [PubMed] [Google Scholar]
  134. Roninson IB. The role of the MDR1 (P-glycoprotein)gene in multidrug resistance in vitroand in vivo. Biochem Pharmacol. 1992;43:95–102. doi: 10.1016/0006-2952(92)90666-7. [DOI] [PubMed] [Google Scholar]
  135. Rose KM, Szopa J, Han FS, Cheng YC, Richter A, Scheer U. Association of DNA topoisomerase and RNA polymerase I: a possible role for topoisomerase I in ribosomal gene transcription. Chromosoma. 1988;96:411–416. doi: 10.1007/BF00303034. [DOI] [PubMed] [Google Scholar]
  136. Rossi F, Labourier E, Forne T, Divita G, Derancourt J, Riou JF, Antoine E, Cathala G, Brunel C, Tazi J. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature. 1996;381:80–2. doi: 10.1038/381080a0. [DOI] [PubMed] [Google Scholar]
  137. Rothenberg ML. Topoisomerase I inhibitors. Annu Oncol. 1997;8:837–55. doi: 10.1023/a:1008270717294. [DOI] [PubMed] [Google Scholar]
  138. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, Donehower RC. Phase I and pharmacological study of topotecan: A novel topoisomerase inhibitor. J Clin Oncol. 1992;10:647–56. doi: 10.1200/JCO.1992.10.4.647. [DOI] [PubMed] [Google Scholar]
  139. Rubin E, Pantazis P, Bharti A, Toppmeyer D, Giovanella B, Kufe D. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-Nitro-camptothecin. J Biol Chem. 1994;269:2433–39. [PubMed] [Google Scholar]
  140. Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzy-Jyun Y, Tao Y, Trochanowski B, Wright P, Barbosa K, Toomasi F, Kelsen D. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors with attempt at dose-intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst. 1993;85:1499–507. doi: 10.1093/jnci/85.18.1499. [DOI] [PubMed] [Google Scholar]
  141. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, Heijningen van THM, van Kalken CK, Slovak ML, de Vries EGE, van der Valk P, Meijer CJLM, Pinedo HM. Overexpression of a Mr 110 000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993;53:1475–79. [PubMed] [Google Scholar]
  142. Shen CC, Shen CKJ. Specificity and flexibility of therecognition of DNA helical structure by eukaryotic topoisomerase I. J Mol Biol. 1990;212:67–78. doi: 10.1016/0022-2836(90)90305-6. [DOI] [PubMed] [Google Scholar]
  143. Shimizu T, Pommier Y. DNA fragmentation induced by protease activation in p53-null human leukemia cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: Cell-free system studies. Exp Cell Res. 1996;226:292–301. doi: 10.1006/excr.1996.0230. [DOI] [PubMed] [Google Scholar]
  144. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993;85:271–91. doi: 10.1093/jnci/85.4.271. [DOI] [PubMed] [Google Scholar]
  145. Smith PJ. DNA topoisomerase dysfunction: a new goal for antitumor chemotherapy. Bioassay. 1990;12:1657–72. doi: 10.1002/bies.950120405. [DOI] [PubMed] [Google Scholar]
  146. Snow K, Judd W. Characterization of adriamycin resistant and amsacrine-resistant human leukaemic T-cell lines. Br J Cancer. 1991;63:17–28. doi: 10.1038/bjc.1991.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  147. Spicer JA, Gamage SA, Atwell GJ, Finlay GJ, Baguley BC, Denny WA. Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem. 1997;40:1919–29. doi: 10.1021/jm970004n. [DOI] [PubMed] [Google Scholar]
  148. Sugarman SM, Zou Y, Wasan K, Poirot K, Kumi R, Reddy S, Perez-Soler R. Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies. Cancer Chem Pharmacol. 1996;37:531–8. doi: 10.1007/s002800050425. [DOI] [PubMed] [Google Scholar]
  149. Sugimoto Y, Tsukahara S, Oh-Hara T, Isoe T, Tsuruo T. Decreased expression of DNA topoisomerase I in camptothecinresistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 1990;50:6925–30. [PubMed] [Google Scholar]
  150. Supino R, Caserini C, Orlandi L, Zaffaroni N, Silvestrini R, Vaglini M, Zunino F. Modulation of melphalan cytotoxic activity in human melanoma cell lines. Anticancer Drugs. 1996;7:604–12. doi: 10.1097/00001813-199607000-00017. [DOI] [PubMed] [Google Scholar]
  151. Taniguchi K, Kohno K, Kawanami K, Wada M, Kanematsu T, Kuwano M. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. Cancer Res. 1996;56:2348–54. [PubMed] [Google Scholar]
  152. Tanizawa A, Pommier Y. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res. 1992;52:1848–54. [PubMed] [Google Scholar]
  153. Tanizawa A, Beitrand R, Kohlhagen G, Tabuchi A, Jenkins J, Pommier Y. Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J Biol Chem. 1993;268:25463–8. [PubMed] [Google Scholar]
  154. Thiebaut T, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA. 1987;84:7735–38. doi: 10.1073/pnas.84.21.7735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Trask DK, Muller MT. Stabilization of type I topoisomerase DNA covalent complexes by actinomycin D. Proc Natl Acad Sci USA. 1988;85:1417–25. doi: 10.1073/pnas.85.5.1417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  156. Trask DK, DiDonato JA, Muller MT. Rapid detection and isolation of covalent DNA protein complexes: application totopoisomerase I and II. EMBO J. 1984;3:671–676. doi: 10.1002/j.1460-2075.1984.tb01865.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  157. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Antitumor effect of CPT-11 a new derivative of camptothecin against pleiotropic drug resistant tumors in vitroand in vivo. Cancer Chemother Pharmac. 1988;21:71–74. doi: 10.1007/BF00262744. [DOI] [PubMed] [Google Scholar]
  158. Turman MA, Douvas A. A Casein Kinase type II (CKII) like nuclear protein kinase associates with, phosphorylates and activates topoisomerase I. Biochem Med Metab Biol. 1993;50:210–225. doi: 10.1006/bmmb.1993.1063. [DOI] [PubMed] [Google Scholar]
  159. Valenti M, Nieves-Neira W, Kohlhagen G, Kohn KW, Wall ME, Wani MC, Pommier Y. Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells. Mol Pharmacol. 1997;52:82–7. doi: 10.1124/mol.52.1.82. [DOI] [PubMed] [Google Scholar]
  160. van der Zee AG, Hollema H, de Jong S, Boonstra H, Gouw A, Willemse PH, Zijlstra JG, de Vries EG. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in maglignant tumors of the ovary, before and after platinium/cyclophosphamide chemotherapy. Cancer Res. 1991;51:5915–20. [PubMed] [Google Scholar]
  161. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol. 1996;50:1536–40. [PubMed] [Google Scholar]
  162. Verweij J, Lund B, Beijnen J, Planting A, de Boer-Dennert M, Koier I, Rosing H, Hansen H. Phase I and pharmacokinetic study of topotecan, a new topoisomerase I inhibitor. Ann Oncol. 1993;4:673. doi: 10.1093/oxfordjournals.annonc.a058623. [DOI] [PubMed] [Google Scholar]
  163. Vinograd J, Lebowtiz J, Radloff R, Waron R, Laipis P. The twisted circular form of polyoma viral DNA. Proc Natl Acad Sci USA. 1965;53:1104–1111. doi: 10.1073/pnas.53.5.1104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  164. Wall ME, Wani NC, Cook CE, Palmer KH, McPhail AT, Sim GA. Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkyloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc. 1966;94:3888. [Google Scholar]
  165. Wang HK, Liu SY, Hwang KM, Taylor G, Lee KH. Synthesis of novel water-soluble 7-(aminoacylhydrazono)-formyl camptothecins with potent inhibition of DNA topoisomerase I. Bioorg Med Chem. 1994;2:1397–402. doi: 10.1016/s0968-0896(00)82091-x. [DOI] [PubMed] [Google Scholar]
  166. Wang HP, Rogler CE. Topoisomerase I-mediated integration of hepadnavirus DNA in vitro. J Virol. 1991;65:2381–92. doi: 10.1128/jvi.65.5.2381-2392.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  167. Wang JC. DNA topoisomerases. Annu Rev Biochem. 1985;54:665–697. doi: 10.1146/annurev.bi.54.070185.003313. [DOI] [PubMed] [Google Scholar]
  168. Wang JC. DNA topoisomerases. Annu Rev Biochem. 1996;65:636–92. doi: 10.1146/annurev.bi.65.070196.003223. [DOI] [PubMed] [Google Scholar]
  169. Wang JC. Interaction between DNA and Escherichia coli omega protein. J Mol Biol. 1971;55:523–533. doi: 10.1016/0022-2836(71)90334-2. [DOI] [PubMed] [Google Scholar]
  170. Wang LK, Johnson RK, Hecht SM. Inhibition of topoisomerase I function by nitidine and fagaronine. Chem Res Toxicol. 1993;6:813–8. doi: 10.1021/tx00036a010. [DOI] [PubMed] [Google Scholar]
  171. Wang LK, Rogers BD, Hecht SM. Inhibition of topoisomerase I function by coralyne and 5,6-dihidrocoralyne. Chem Res Toxicol. 1996;9:75–83. doi: 10.1021/tx950080y. [DOI] [PubMed] [Google Scholar]
  172. Wani MC, Ronman PE, Lindley JT, Wall ME. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J Med Chem. 1980;23:554–60. doi: 10.1021/jm00179a016. [DOI] [PubMed] [Google Scholar]
  173. Xie G, Gupta R, Atchison K, Lown JW. Bisindolylmaleimides linked to DNA minor groove binding lexitropsins. synthesis, inhibitory activity against topoisomerase I, and biological evaluation. J Med Chem. 1996;39:1049–55. doi: 10.1021/jm950465d. [DOI] [PubMed] [Google Scholar]
  174. Yang CHJ, Cowan KH and Schneider E (1993) Quantitative PCR for DNA topoisomerase I, II alpha, II beta and mdr1 in cell lines and tumor samples. Proc Annu Meet Am Assoc Cancer Res 34: A56.
  175. Yang CHJ, Horton JK, Cowan KH, Schneider E. Crossresistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res. 1995;55:4004–9. [PubMed] [Google Scholar]
  176. Zhang H, Wang JC, Liu LF. Involvement of DNAtopoisomerase I in transcription of human ribosomal RNA genes. Proc Natl Acad Sci USA. 1988;85:1060–1064. doi: 10.1073/pnas.85.4.1060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  177. Zhang H, D'Arpa P. A model tumor cell killing by topoisomerase poisons. Cancer Cells. 1990;2:23–27. [PubMed] [Google Scholar]
  178. Zhao R, Al-Said NH, Sternbach DL, Lown JW. Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro. J Med Chem. 1997;40:216–25. doi: 10.1021/jm9605804. [DOI] [PubMed] [Google Scholar]
  179. Zhou BS, Bastow KF, Cheng YC. Characterization of 3′-region of the human DNA topoisomerase I gene. Cancer Res. 1989;49:3922–3927. [PubMed] [Google Scholar]
  180. Zijlstra JG, De Jong S, De Vries EGE, Mulder NH. Topoisomerases, new targets in cancer chemotherapy. Med Oncol Tumor Pharmacother. 1990;7:11–18. doi: 10.1007/BF03000485. [DOI] [PubMed] [Google Scholar]

Articles from Cytotechnology are provided here courtesy of Springer Science+Business Media B.V.

RESOURCES